Clinical Trials Directory

Trials / Unknown

UnknownNCT05015829

Diagnostic Impact of Low-dose Dobutamine Echocardiography in Low-flow Low-gradient Aortic Stenosis

Status
Unknown
Phase
Study type
Observational
Enrollment
150 (estimated)
Sponsor
Odense University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

When aortic valve-area is \<1.0cm2 and transvalvular mean-gradient is \>40mmHg, the diagnosis of severe aortic stenosis (AS) is straightforward. However, some patients present with an apparently reduced valve-area, despite transvalvular-gradient \<40mmHg; Low-flow, low-gradient aortic stenosis (LFLG AS). When a patient with LFLG AS also presents with LVEF \<50%, guidelines recommends performing a Low-Dose Dobutamine-echocardiography (LDDE) to confirm true-severe AS. However, nearly 30% of patients with LFLG AS do not show an adequate respond to Dobutamine. More commonly, patients present with the combination of LFLG AS, despite LVEF≥50%. In this group of patients the use of LDDE remains undisclosed. The purpose of this study is to examine the safety and diagnostic usefulness of LDDE in patients with LFLG AS with LVEF≥50%. Furthermore we will examine factors associated with inadequate response to LDDE. 150 symptomatic and/or asymptomatic patients with LFLG and LVEF≥50% and a control group with LVEF\<50% will be enrolled at the Department of Cardiology, OUH. Patients will undergo clinical evaluation including LDDE, blood analyses, CT-scan and cardiac Mri. Only a limited number of studies examine the possible use of LDDE in patients with LFLG AS and LVEF≥50% and no study has been performed documenting the safety and feasibility.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTDobutamine Stress EchocardiographyChange in echocardiographic 2D and doppler measurements during infusion with Dobutamine 5 µg/kg/min till max dosage of 20 µg/kg/min.

Timeline

Start date
2019-09-01
Primary completion
2021-09-01
Completion
2022-08-31
First posted
2021-08-20
Last updated
2021-08-20

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT05015829. Inclusion in this directory is not an endorsement.